DIA/EFGCP/EMA Conference on How to Optimise Children's Access to Innovative Medicines

16-17 October 2017

European Medicines Agency, London, UK

PROGRAMME COMMITTEE

DIA

Heidrun Hildebrand
Global Program Head, TA Pediatric Development
Bayer, Germany

Mette Due Theilade Thomsen
Managing Director
PIP Adviser, Denmark

Geneviève Le Visage
Head EU Regulatory Policy
Novartis Pharma, Switzerland

EMA

Roberto De Lisa
Scientific Officer, Paediatric Medicines Office
European Medicines Agency, European Union

Janina Karres
Scientific Officer, Paediatric Medicines Office
European Medicines Agency, European Union

EFGCP

Dimitrios Athanasiou
Patient Advocate
Muscular Dystrophy Association Hellas, Greece

Solange Corriol-Rohou
Senior Director, Global Regulatory Affairs & Policy, Europe
AstraZeneca Global Medicines Development, France

Martine Dehlinger-Kremer
Vice President, Global Medical and Regulatory Affairs
SynteractHCR, Germany; President of EUCROF, The Netherlands

OVERVIEW

In 2017, the DIA/EFGCP/EMA Annual Paediatric Conference will focus on how to optimise children's access to new medicines.

With more than 10 years of the EU Paediatric Regulation, all stakeholders involved in paediatric drug development have seen progress in developing new medicines for children.

This conference will explore how to build on the successes from the past 10 years of EU Paediatric Regulation, and how to overcome challenges that still exist.

Day 1: 10 years of Paediatric Regulation: Lessons Learnt from All Stakeholders

- Real world examples of what challenges are associated with different regulatory pathways and development scenarios as well as how to overcome them. Case studies will be presented to foster the discussion in rare diseases/small populations as well as oncology
- Discussions on tools and methods appropriate to optimise drug development such as extrapolation
- Concluding session on patient engagement within decision-making processes. What are patients' groups expectations regarding availability of new medicines and how do they define benefit/risk?

Day 2: Looking Toward the Future

Updates from ongoing European and International initiatives related to paediatric, including clinical trials

- Discussions on possible opportunities with the new European Clinical Trials Regulation when conducting paediatric clinical trials
- Quest for solutions within paediatric pharmacovigilance with a view to promote shared understanding with all parties
- Concluding sessions on exploring the future of children's access to new medicines. Different stakeholders face different challenges that are unique to Europe, while paediatric medicines development is global. This session aims to promote a common understanding and alignment on important points from different stakeholders and will set the scene for future dialogue.

There will be a specific Q&A session with EMA on paediatric procedures.

OBJECTIVES

- To update participants on current paediatric regulatory requirements, scientific and operational success and challenges
- To exchange experiences with regulatory authorities, academia and industry when developing medicines for children globally
- To discuss visions, daily challenges and potential ways to move forward and further improve processes for paediatric drug development

WHO SHOULD ATTEND

- Regulatory, clinical and drug development professionals from Health Authorities and Industry interested in paediatric drug development
- Paediatricians, Representatives from Academia, Paediatric Societies and Networks
- Employees from Clinical Research Organisations (CROs) involved in paediatric clinical trials
- Any stakeholder interested in the development of better medicines for children

How to Optimise Children's Access to Innovative Medicines

DAY ONE I MONDAY, 16 OCTOBER

08:00 REGISTRATION AND WELCOME COFFEE

08:30 OPENING REMARKS

Heidrun Hildebrand, Global Program Head, TA Pediatric Development, Bayer, Germany

Solange Corriol-Rohou, Senior Director, Global Regulatory Affairs & Policy, Europe, AstraZeneca Global Medicines Development, France

Enrica Alteri, Head, Human Medicines Research and Development Support Division, European Medicines Agency (EMA), European Union

09:00 KEYNOTE SPEECH

10 YEARS OF PAEDIATRIC REGULATION - WHERE WE ARE TODAY (CHALLENGES AND OPPORTUNITIES)

Florian Schmidt, Deputy Head of Unit B5 – Medicines: Policy, Authorisation and Monitoring, DG SANTE, European Commission, Belgium

09:30 SESSION 1

DOES THE REGULATION DELIVER ON ITS GOAL OF IMPROVING AVAILABILITY OF NEW MEDICINES TO PAEDIATRIC PATIENTS IN EUROPE?

Session Chair: **Solange Corriol-Rohou**, Senior Director, Global Regulatory Affairs & Policy, Europe, AstraZeneca Global Medicines Development, France

Setting the scene...With 10 years of paediatric regulation, hundreds of agreed Paediatric Investigation Plans in place and a growing number of ongoing paediatric clinical trials one question has still to be answered: will all these efforts also lead to increased availability of new medicines to patients and prescribers in Europe? The session will give an overview on the status quo from different stakeholders and what might still be needed.

The Regulators' Perspective

Michael Berntgen, Head of Product Development Scientific Support Department, European Medicines Agency (EMA), European Union

The Academia/Prescribers' Perspective

Gilles Vassal, Head of Clinical Research Division, Institute Gustave Roussy, France

The Industry Perspective

Bruno Flamion, VP, Head Strategic Development, Idorsia Pharmaceuticals, Switzerland

The Patients' Perspective

Dimitrios Athanasiou, Patient Advocate, Muscular Dystrophy Association Hellas, Greece

The Payers' Perspective

Representative Invited

10:45 COFFEE BREAK

11:15 SESSION 2

HOW TO OPTIMIZE DRUG DEVELOPMENT UP TO APPROVAL AND BEYOND - PARALLEL BREAKOUT SESSIONS WITH CASE STUDIES

Session Chair: **Martine Dehlinger-Kremer**, Vice President, Global Medical and Regulatory Affairs, SynteractHCR, Germany; President of EUCROF, The Netherlands

In the breakout sessions real world cases will give an overview of the challenges to overcome when developing medicinal products for children with rare diseases or cancer. When and how to use extrapolation, which could help optimise drug development, will also be addressed.

SESSION 2A

RARE DISEASE/SMALL POPULATION

Session Chair:
Lutz Harnisch, Senior Director, Global Clinical Pharmacology/Pharmacometrics, Pfizer, United Kingdom

Presenters: Laura Fregonese, Scientific Officer, European Medicines Agency (EMA), European Union
Dunja Pfeiffer, Head Market Access DACH Area, Pierre Fabre Pharma, Germany
Stephanie Rosenfeld, Director, Evidence Based Medicine/ Health Economics and Outcomes Research, Sanofi-Aventis, Germany

Rapporteurs: Laura Fregonese, Scientific Officer, European Medicines Agency (EMA), European Union
Heidrun Hildebrand, Global Program Head, TA Paediatric Development, Bayer, Germany

SESSION 2B

ONCOLOGY, PRELIMINARY DATA

Session Chair:
Solange Corriol-Rohou, Senior Director, Global
Regulatory Affairs & Policy, Europe, AstraZeneca
Global Medicines Development, France

Presenters: Meike Angstenberger, Senior Global Program Regulatory Manager, RA Oncology, Novartis Pharma, Switzerland
George Kirk, Global Medicines Lead, AstraZeneca, United Kingdom
Amy Cheung, Senior Pharmacometrician, Early Clinical Development, AstraZeneca, United Kingdom

SESSION 2C

EXTRAPOLATION – APPLICATION OF THE EMA EXTRAPOLATION FRAMEWORK

Session Chairs:
Cécile Ollivier, Scientific Officer, Science and Innovation Support Office, European Medicines Agency (EMA), European Union
Christina Bucci-Rechtweg, Global Head, Pediatric & Maternal Health Policy, Drug Regulatory Affairs, Novartis Pharmaceuticals, United States

Presenters: Lynne Yao, Director, Division of Pediatric and Maternal Health, Office of New Drugs, Food and Drug Administration (FDA), United States - *presenting remotely*
Darren Austin, Senior Fellow and Senior Director, Clinical Pharmacology, GSK, United Kingdom
Sabine Derey, Regulatory Manager, Respiratory Therapeutic Group, GSK, United Kingdom
Rapporteur: Andrew Thomson, Statistician, Biostatistics & Methodology Support Office, European Medicines Agency (EMA), European Union

13:15 LUNCH

14:00 SESSION 3

REPORTS AND CONCLUSION FROM BREAKOUT SESSIONS & EMA UPDATE

Session Chair:

Mette Due Theilade Thomsen, Managing Director, PIP Adviser, Denmark

Following the feedback from the 3 breakout sessions, the session will be the opportunity for EMA Paediatric Division to provide the attendees with an update on EMA paediatric activities, and to answer specific questions sent by the attendees for EMA and/or PDCO prior to the Conference.

Feedback from the Breakout Sessions

Rapporteurs of the BOS

Update from EMA on Paediatric Related Matters and Q&A

Ralph Bax, Head of the Paediatric Medicines Office, European Medicines Agency (EMA), European Union
Peter Karolyi, Scientific Officer, European Medicines Agency (EMA), European Union
Koenraad Norga, Head of Clinic, Paediatric Oncology, Antwerp University Hospital, Belgium; Paediatric Committee (PDCO) Vice-Chair

15:30 COFFEE BREAK

16:00 SESSION 4

HOW ARE CHILDREN, CARERS AND FAMILIES CONTRIBUTING TO THE DECISION MAKING?

Session Chair:

Katie Rizvi, Founder, Little People Association & Temerarii Club, Romania

The session will focus on the contribution of the patients' organisations to the decision-making processes – at the level of EMA and the HTA bodies, using case examples. How these organisations define a product's benefit/risk, what they are expecting, e.g. availability of new medicines (data, timing, and availability across Europe), and what level of uncertainties they are ready to accept.

Panel discussion with Q&A

Panellists:
Nathalie Bere, Patient Relations Coordinator, European Medicines Agency (EMA), European Union
Yvonne Schmidt, Federal Joint Committee (G-BA), Germany
Anna Sherriffs, Young Patient Advocate, Young Persons' Advisory Group (YPAG) Scotland, United Kingdom

17:30 NETWORKING RECEPTION

All delegates are invited to take part in the networking reception, which will be hosted at the EMA. This will be a very special occasion for continuing the discussions with colleagues.

During this reception, a lecture on "Challenges and Opportunities/Solutions in Treatment of Neonatal Patients" will be given by Mark Turner, Senior Lecturer in Neonatology, University of Liverpool, United Kingdom.

19:00 END OF DAY ONE

Continuing Education

SwAPP and SGPM Credits

DIA meetings and training courses are approved by the SwAPP (Swiss Association of Pharmaceutical Professionals) Commission for Professional Development (CPD) and SGPM (Swiss Society of Pharmaceutical Medicine) and are honoured with credits for pharmaceutical medicine. All meeting and training course participants are eligible for applicable credits.

This conference has been accredited with 14.25 credits.

FPM RCP Credits

DIA has been awarded with Continuing Professional Development (CPD) credits from the Faculty of Pharmaceutical Medicine of the Royal College of Physicians of the United Kingdom for selected meetings and training courses. Physicians who are eligible for these credits can find more information about registering for CPD on https://www.fpm.org.uk/revalidationcpd/CPD/cpd. Already registered CPD members can claim the applicable credits directly on https://www.revalidation.fpm.org.uk/login.

This conference has been accredited with 14.25 credits.

Conference Venue

European Medicines Agency
30 Churchill Place
Canary Wharf
London E14 5EU
United Kingdom

Tel. +44 (0)20 3660 6000
Fax: +44 (0)20 3660 5555
www.ema.europa.eu

DAY TWO | TUESDAY, 17 OCTOBER

08:30 REGISTRATION AND WELCOME COFFEE

09:00 SESSION 5

PAEDIATRIC RELATED INITIATIVES: UPDATE ON PROGRESS

Session Chairs:
Janina Karres, Scientific Officer, Paediatric Medicines Office, European Medicines Agency (EMA), European Union
Roberto De Lisa, Scientific Officer, Paediatric Medicines Office, European Medicines Agency (EMA), European Union

This session will give an overview of currently ongoing initiatives that foster understanding and development of new medicines for children and discuss how all these initiatives support the goals of the Paediatric Regulation.

New GVP – Population-Specific Considerations, Paediatric Population
Jolanta Gulbinovič, PRAC Member, State Medicines Control Agency, Lithuania

Industry Experience to PV / Risk Management in Paediatrics
Jacqueline Phillips, Director, Pediatric Product Development, Johnson & Johnson, United States

The Patient Registry Initiative and Paediatric Aspects
Patricia McGettigan, Clinical Pharmacologist, Pharmacoepidemiology Group, European Medicines Agency (EMA), European Union

Upcoming New Clinical Trials Regulation
Seán Kilbride, Assessor (Clinical Assessment), Health Products Regulatory Authority (HPRA), Ireland

10:30 COFFEE BREAK

11:00 SESSION 5 CONTINUED

ICH S11 Guideline
Georg Schmitt, Head Toxicology (Operations) and Nonclinical Paediatrics, F. Hoffmann-La Roche, Switzerland; EFPIA deputy topic leader

Revision of the ICH E11 Guideline
Solange Corriol-Rohou, Senior Director, Global Regulatory Affairs & Policy, Europe, AstraZeneca Global Medicines Development, France; EFPIA topic leader

European Projects of Interest:

1. **IMI2: Paediatric Preclinical Proof of Concept (POC) platform**
   Stefan Pfister, Head of Division Paediatric Neurooncology, German Cancer Research Center (DKFZ) Heidelberg, Germany
2. **IMI2: Pan European Paediatric Clinical Trials Network**
   Heidrun Hildebrand, Global Program Head, TA Paediatric Development, Bayer, Germany; Co-Lead EFPIA Consortium
3. **The FP7 Advances in Small Trials dEsign for Regulatory Innovation and eXcellence (ASTERIX) project**
   Kit Roes, Professor, Clinical Trial Methdology, University Medical Center Utrecht, The Netherlands

13:00 LUNCH

14:00 SESSION 6

LOOKING AT THE FUTURE

Session Chair: **Mark Turner**, Senior Lecturer in Neonatology, University of Liverpool, United Kingdom

This session will be the opportunity to look at the future and discuss how to overcome the remaining challenges and optimise opportunities to deliver innovative and efficient drugs that address children's needs. All stakeholders have key roles and responsibilities in bringing new and beneficial medicines to Children in Europe. They face different challenges that are unique to Europe, while medicines are developed for global purpose. This panel discussion aims to promote common understanding and alignment on some important points from different stakeholders and will set the scene for future dialogue.

Panellists:
- Ralph Bax, Head of the Paediatric Medicines Office, European Medicines Agency (EMA), European Union
- Gilles Vassal, Head of Clinical Research Division, Institute Gustave Roussy, France
- Dimitrios Athanassiou, Patient Advocate, Muscular Dystrophy Association Hellas, Greece
- Payer Representative Invited
- Vinciane Pirard, Senior Director, Public Affairs (Europe & International), Sanofi-Genzyme, Belgium
- Siri Wang, Scientific Director, Norwegian Medicines Agency, Norway; Paediatric Committee (PDCO) Member

Introduction

Panellists' view
- Based on the experience so far, what could be the future for drug development and drug access in paediatrics?
- How to plan for a fit for purpose and successful clinical programme
- Targeting stakeholder's interactions and engagement
- Roles of existing networks and (future) EU initiatives

Panel discussion with Q&A

Conclusions

16:00 END OF CONFERENCE

How to Optimise Children's Access to Innovative Medicines

Evaluation

We value your feedback on the content and organisation of this conference. The electronic survey will be sent to you after the conference.

Access Presentations

As a benefit of your registration, presentations are made available on www.diaglobal.org.

- Presentations are made available to full conference attendees only (Attendee, Exhibitor, Speaker, and Press badges).
- To access presentations, go to *My Presentation Downloads* and log in when prompted
- No paper copies of the presentations will be provided

NOTE: If a presentation is not available, the speaker either did not agree to publish it or did not provide us with their presentation. Updated versions of the slides will be made available shortly after the conference.

NOTE: You will need to enter your DIA User ID and password to verify your status. If you have forgotten your DIA User ID and password, use our Login Reminder.

In *My Presentation Downloads* you will see presentation PDFs from all the DIA offerings you have attended in the past 6 months. Simply choose the presentation you would like to view or download.

Certificate of Attendance

A Certificate of Attendance will be sent to all attendees electronically during the next few days. Please note certification requires full attendance. For more information please liaise with our DIA Contact Centre on diaeurope@diaeurope.org or call +41 61 225 51 51.

About DIA

DIA is the global connector in the life sciences product development process. Our association of more than 18,000 members builds productive relationships by bringing together regulators, innovators, and influencers to exchange knowledge and collaborate in an impartial setting. DIA's network creates unparalleled opportunities for exchange of knowledge and has the inter-disciplinary experience to prepare for future developments.

The dedicated efforts of DIA staff, members and speakers enable DIA to provide a comprehensive catalogue of conferences, workshops, training courses, scientific publications and educational materials. DIA is a global community representing thousands of stakeholders working together to bring safe and effective products to patients.

DIA is an independent, non-profit organisation has its Global Center in Washington, DC, USA with the European office in Basel, Switzerland, and additional regional offices in Horsham, Pennsylvania, USA; Tokyo, Japan; Mumbai, India; and Beijing, China.

Group Discounts

Register 3 individuals from the same company and receive a 50% discount for a 4th! All 4 individuals must register and prepay at the same time without exception. DIA will apply the value of the lowest applicable fee to this discounted registration; it does NOT include fees for optional events or DIA membership. You may substitute group participants of the same membership status at any time; however, administrative fees may be incurred.

Group registration is not available online and only available for the industry rate.

To take advantage of this offer, please print the registration form for each of the four registrants from your company. Include the names of all four group registrants on each of the forms and return them together to DIA.

For groups of 5 or more individuals, please contact Zsofia.Molnar@DIAglobal.org for a custom group rate.

Follow **@DrugInfoAssn**

REGISTRATION FORM | ID# 17122

How to Optimise Children's Access to Innovative Medicines | 16-17 October 2017 | London, UK

DIA

Early-bird discount and Advance rate

To qualify for the discount, registration form and accompanying payment must be received by the dates below. Early-bird/Advance rate applies to industry members only.

Early bird discount: register by 24 July 2017 **€ 1'230.00** ❑

Advance rate: register by 4 September 2017 **€ 1'330.00** ❑

CATEGORY	DIA/EFGCP Member *	Non-Member*
Industry	€ 1'430.00 ❑	€ 1'585.00 ❑
Government/Charitable/Non-profit/Academia (Full-Time)	€ 715.00 ❑	€ 870.00 ❑

If DIA/EFGCP cannot verify your membership upon receipt of registration form, you will be charged the non-member fee . Group discount/SME rates available. Special rates for students and patient representatives on offer, subject to avaibility. Please contact DIA EMEA for more information.
Registration fee includes: refreshments, lunches, reception and meeting materials.

*All fees are subject to the applicable VAT. Payment due 30 days after registration and must be paid in full by commencement of the event.

TOTAL AMOUNT DUE: € _____

ATTENDEE DETAILS

PLEASE COMPLETE IN BLOCK CAPITAL LETTERS OR MAKE REGISTRATION EVEN SIMPLER BY ATTACHING THE ATTENDEE'S BUSINESS CARD HERE

❑ Prof ❑ Dr ❑ Ms ❑ Mr

Last Name

First Name

Company

Job Title

Address

Postal Code City

Country

Telephone

Fax

Attendee email required to access presentations

Please provide your European VAT number

PAYMENT METHODS

Credit cards: Payments by VISA, Mastercard or AMEX can be made by completing the details below. Please note that other types of credit card cannot be accepted.

❑ **Please charge my** ❑ VISA ❑ MC ❑ AMEX

Card N°

Exp. Date /

Cardholder's Name

❑ **Bank transfers:** When DIA completes your registration, an email will be sent to the address on the registration form with instructions on how to complete the bank transfer. Payments in EURO should be addressed to "Account Holder: DIA." Please include your name, company, Event ID#17122 as well as the invoice number to ensure correct allocation of your payment.

Payments must be net of all charges and bank charges must be borne by the payer. **If you have not received your confirmation within five working days, please contact DIA Europe, Middle East and Africa.**

By signing below, I confirm that I agree with DIA's Terms and Conditions of booking. These are available from the office or online by clicking **here.**

Date	Signature

DIA MEMBERSHIP

Join DIA now to qualify to save on future events and to receive all the benefits of membership. Visit www.DIAglobal.org and click on Membership for more details.

DIA offers one year complimentary membership against event registration at non-member rate

❑ **I do not want complimentary membership**

TERMS AND CONDITIONS

Cancellations

All cancellations must be made in writing and be received at the DIA Europe, Middle East and Africa office four weeks prior to the event start date. Cancellations are subject to an administrative fee:

- Industry (Member/Non-member) € 200.00
- Academia/Charitable/Government/Non-profit (Full-time) (Member/Non-member) € 100.00

For cancellations after this date, or if the delegate fails to attend the meeting, no refund of fees will be given and be responsible for the full registration fee. DIA EMEA reserves the right to alter the venue and dates if necessary. If an event is cancelled, DIA EMEA is not responsible for airfare, hotel or other costs incurred by registered attendees. Registered attendees are responsible for cancelling their own hotel and travel reservations.

Transfer Policy

You may transfer your registration to a colleague prior to the start of the event but membership is not transferable. Substitute attendees will be responsible for the non-member fee, if applicable. Please notify the DIA EMEA office of any such substitutions as soon as possible.

Photography and Video Policy

By attending the event, you give permission for images of you, captured during the conference through video, photo, and/or digital camera, to be used by DIA in promotional materials, publications, and website and waive any and all rights including but not limited to compensation or ownership.

The DIA Europe, Middle East & Africa Contact Center will be pleased to assist you with your registration from Monday to Friday between 08:00 and 17:00 CET.

Email emea@DIAglobal.org
Tel. +41 61 225 51 51
Fax +41 61 225 51 52
Web www.DIAglobal.org
Mail DIA EMEA, Kuechengasse 16, 4051 Basel, Switzerland